  1.2 Annex to Application Form 
List of all authorised product presentations 
MA (EU) number 
(Invented) name 
Strength  Pharmaceutical 
form 
Route of 
administration 
Immediate 
Packaging 
<Content 
(concentration)> 
Pack size 
EU/1/12/812/001 
Bexsero 
--1 
Suspension for 
injection 
Intramuscular 
use 
EU/1/12/812/002 
Bexsero 
--1 
Suspension for 
injection 
Intramuscular 
use 
EU/1/12/812/003 
Bexsero 
--1 
Suspension for 
injection 
Intramuscular 
use 
EU/1/12/812/004 
Bexsero 
--1 
Suspension for 
injection 
Intramuscular 
use 
pre-filled 
syringe 
(glass) 
pre-filled 
syringe 
(glass) 
pre-filled 
syringe 
(glass) 
pre-filled 
syringe 
(glass) 
0.5 ml 
0.5 ml 
0.5 ml 
0.5 ml 
1 pre-filled 
syringe 
with 
needles 
1 pre-filled 
syringe 
without 
needles 
10 pre-filled 
syringes 
with 
needles 
10 pre-filled 
syringes 
without 
needles 
--1  One dose (0.5 ml) contains: 
Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3 
                             50 micrograms 
Recombinant Neisseria meningitidis group B NadA protein 1, 2, 3 
                                        50 micrograms 
Recombinant Neisseria meningitidis group B fHbp fusion protein 1, 2, 3                                         50 micrograms 
Outer membrane vesicles (OMV) from Neisseria meningitidis group B  
strain NZ98/254 measured as amount of total protein containing the PorA P1.4 2 
                  25 micrograms 
1 produced in E. coli cells by recombinant DNA technology 
2 adsorbed on aluminium hydroxide (0.5 mg Al3+) 
3 NHBA (Neisserial Heparin Binding Antigen), NadA (Neisseria adhesin A), fHbp (factor H binding protein) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
